Global Commercialization Strategy Sample Clauses

Global Commercialization Strategy. Before the Commencement of the first Registrational Study for any Collaboration Product following the exercise of the Merck Participation Election for the applicable Program, Merck shall provide, and within [***] days after such provision the JCC will review and update for approval by the JSC, a written summary of the global Commercialization strategy for all Collaboration Products included in the Joint Development Plan and Budget for the applicable Program in the Territory. Such strategy should include [***]. For clarity, any and all such communications and strategy involving the Commercialization of a Collaboration Product will be limited to those permitted under applicable Law, including antitrust Laws.
View SourceView Similar (4)
Global Commercialization Strategy. For each Split Territory Licensed Product, the key Commercialization principles will be set forth in a written summary of the global Commercialization strategy for such Split Territory Licensed Product approved by the PSC for such Split Territory Licensed Product (each, a “Global Commercialization Strategy”). The PSC responsible for the applicable Split Territory Licensed Product shall prepare the initial draft of such Global Commercialization Strategy within [***] for such Split Territory Licensed Product, and then annually thereafter. Amendments to any Global Commercialization Strategy will become effective following review and approval by the applicable PSC.
View SourceView Similar (4)
Global Commercialization Strategy. The JCC shall prepare for the approval of the JSC the initial draft of such Global Commercialization Strategy within [***] months after initiation of the first Pivotal Clinical Study for a CoDev Product, which shall be updated and approved annually thereafter. Amendments to any Global Commercialization Strategy will become effective following review and approval by the JSC.
View SourceView Similar (3)
Global Commercialization Strategy. For each Licensed Product, the key Commercialization principles will be set forth in a written summary of the global Commercialization strategy for such Licensed Product approved by the JSC (each, a “Global Commercialization Strategy”). The JSC shall prepare the initial draft of such Global Commercialization Strategy at the appropriate timing determined by the Parties, but no less than [***] prior to expected Regulatory Approval of such Licensed Product, and then annually thereafter. Amendments to any Global Commercialization Strategy will become effective following review and approval by the JSC.
View SourceView Similar (2)
Global Commercialization Strategy. Fate acknowledges that ▇▇▇▇▇▇▇’▇ global commercialization strategy for the Profit Share Product will inform the U.S. Commercialization Plan. ▇▇▇▇▇▇▇ will develop, with input from Fate through its participation on the USJCC, the global commercialization strategy, which will set forth overall brand strategy/stewardship elements for the Profit Share Product, including brand name, trademarks, global positioning, global messaging, competitive readiness, life cycle management, and guidance for medical affairs and other functions. ▇▇▇▇▇▇▇ will provide the JSC with a copy of the global commercialization strategy and any updates on a quarterly basis, for review and discussion (but not approval) by the JSC.
View Source
Global Commercialization Strategy. Subject to JCC oversight, the Parties’ joint Commercialization of Licensed Products in the Territory shall be guided by an over-arching high-level, general Commercialization strategy that the Parties create jointly, including the global positioning, global brand plan, global branding strategy, global [***] strategy, revenue forecast, global market access, and timing of Launch and Launch sequence of Licensed Products (the “Global Commercialization Strategy”); provided that, for clarity, if there is a dispute over the joint creation of the Global Commercialization Strategy, the matter will be determined by the JCC. The Global Commercialization Strategy shall be determined by the JCC at least [***] prior to the anticipated first Launch of the Licensed Product and updated as appropriate.
View Source
Global Commercialization Strategy. No less than [***] prior to the reasonably anticipated date for a First Commercial Sale of a Product in the Territory, Forty Seven shall prepare and present at the next-occurring JSC meeting for discussion a global sales and marketing strategy (e.g., reimbursement, positioning, segmentation, sales force, messaging and branding) for the Products worldwide (such strategy, and any amendments thereto, the “Global Commercialization Strategy”). Subject to Section 3.3.2, each Party’s Commercialization Plan of the Products in each Territory shall be, to the extent reasonably practicable, aligned with the Global Commercialization Strategy.
View Source
Global Commercialization Strategy. [****] PARTNER shall develop and provide to REGENX through the JCC a global commercialization strategy for such Licensed Product in a particular Indication throughout the Territory (each, a “Global Commercialization Strategy”), which Global Commercialization Strategy shall include [****]. For the avoidance of doubt, this Section 4.2.1 shall apply for each Licensed Product for use in a particular (different) Indication in the Licensed Field (e.g. if a Global Commercialization Strategy has been established for a Licensed Product for use in nAMD, this Section 4.2.1 shall apply again for a Licensed Product for use in DR). Each Global Commercialization Strategy shall be non-binding and shall be used solely to facilitate discussion between the Parties regarding PARTNER’s Commercialization plans in the Territory.
View Source
Global Commercialization Strategy 
View SourceView Similar (2)

Related to Global Commercialization Strategy

  • Joint Commercialization Committee (a) Within thirty (30) calendar days following the Effective Date, the Parties shall establish a JCC to oversee, review and coordinate the activities of the Parties regarding the Commercialization of the Product in the Licensor Territory and the Licensee Territory, subject to the provisions of this Section 8.2. (b) The JCC shall: (i) Review and discuss market access and reimbursement/pricing strategies for Product (and substantive amendments and updates thereto), including formulary strategy; (ii) Provide a forum for coordination of each Party’s activities described in Section 7.5; and (iii) Perform such other duties and responsibilities as are specifically assigned to the JCC by mutual written agreement of the Parties, except where in conflict with any provision of this Agreement. (c) The JCC shall be composed of an equal number of representatives from each of Licensee and Licensor, selected by such Party. Unless the Parties otherwise agree, the exact number of representatives for each of Licensee and Licensor shall be, with respect to the JCC, two (2) representatives. Either Party may replace its respective JCC representatives at any time with prior written notice to the other Party; provided that the criteria for composition of the JCC set forth in the preceding sentence continues to be satisfied following any such replacement of a Party’s representative on the JCC. (d) The JCC shall meet at least twice a year, or at such other intervals as agreed to by the Parties. All JCC meetings may be conducted by telephone, video-conference or in person as determined by the JCC. Each Party shall bear its own personnel and travel costs and expenses relating to JCC meetings. With the consent of the Parties (not to be withheld unreasonably), other appropriate employee representatives of the Parties may attend the JCC meeting as non-voting observers. (e) Decisions for the JCC shall be made as follows: (i) Decisions of the JCC shall be made by unanimous vote, with at least one (1) representative from each Party participating in any vote. (ii) In the event that the JCC does not reach consensus with respect to a particular matter within five (5) Business Days after the matter is submitted to the JCC, then either Party may, by written notice to the other Party, have such matter referred to the Parties’ respective Senior Executives, who shall meet promptly and negotiate in good faith to attempt to resolve the dispute. (iii) If, despite such good faith efforts, the Senior Executives are unable to resolve such dispute during such meeting, then: (A) if such dispute relates to any activities the sole occurrence and effect of which are in the Licensee Territory, then Licensee shall have the right to cast the deciding vote on such matter; and (B) for any other matters to be decided by the JCC, Licensee shall have the right to cast the deciding vote on such matter. (iv) For clarity, neither Party shall have the right to cast a deciding vote to excuse itself from any of its obligations specifically enumerated under this Agreement.